Data from trials like RIGHT Choice demonstrates that a CDK4/6 inhibitor with endocrine therapy is superior to combination chemotherapy, even for patients with aggressive features like symptomatic visceral metastases. This provides compelling evidence to avoid initial chemotherapy in this population.

The Right Choice trial shows CDK4/6 inhibitors are safer and better at delaying cancer progression than chemotherapy for patients with visceral metastases. However, this advantage doesn't translate to longer overall survival, suggesting the key benefit is improved quality of life and a less complex treatment regimen rather than longevity.

Ladera showed a significant benefit for geridesterant over standard endocrine therapy in early breast cancer with an efficacy signal similar to initial readouts for CDK4/6 inhibitors. Since CDK4/6 inhibitors were excluded, this creates a clinical debate: are these treatments interchangeable, sequential, or for different populations?

Experts assert that chemotherapy should not be used as first-line treatment for HR-positive metastatic breast cancer. Clinical trials show a CDK4/6 inhibitor with endocrine therapy provides better outcomes and tolerability than multi-agent chemotherapy, even for patients with aggressive, symptomatic visceral metastases, challenging the traditional use of chemo for rapid response.

In a subset analysis of the high-risk MONARCH-E trial, an inferred Oncotype score did not identify which patients benefited from the CDK4/6 inhibitor abemaciclib. This indicates that while such scores assess prognostic risk and guide chemotherapy decisions, they are not predictive biomarkers for selecting patients for this targeted therapy.

Three major trials (RIGHT Choice, PADMA, OMBRE) definitively show that starting with a CDK4/6 inhibitor plus endocrine therapy is superior to upfront chemotherapy for newly diagnosed, symptomatic metastatic breast cancer. This approach provides better progression-free survival without the toxicity of chemotherapy and, critically, does not result in a slower time to response.

For high-risk, HR+ patients with germline BRCA mutations, data suggest they derive less benefit from CDK4/6 inhibitors. A practical approach is to give one year of the PARP inhibitor olaparib first, followed by a CDK4/6 inhibitor, capitalizing on the delayed initiation allowance in major trials.

When choosing an adjuvant CDK4/6 inhibitor for high-risk HR+ breast cancer, clinicians favor abemaciclib. The key deciding factors are its proven overall survival (OS) benefit from the MonarchE trial and a more appealing two-year treatment course, compared to ribociclib's three-year duration and not-yet-mature OS data.

In high-risk, BRCA-positive patients eligible for both, clinicians favor giving a PARP inhibitor first. The rationale is based on established survival data, shorter one-year duration, and emerging biological evidence suggesting BRCA2-mutated tumors may be resistant to CDK4/6 inhibitors due to concurrent RB gene loss.